The role of CD109 antigen in glioma

ZHOU Pinghui, CAO Sijie, YUE Dong, DONG Fengyun

doi:10.16352/j.issn.1001-6325.2024.12.1731

Jichu yixue yu linchuang (Dec 2024)

The role of CD109 antigen in glioma

ZHOU Pinghui, CAO Sijie, YUE Dong, DONG Fengyun

Affiliations

ZHOU Pinghui, CAO Sijie, YUE Dong, DONG Fengyun: 1. Department of Clinical Medicine, Jining Medical University, Jining 272067; ;2. Department of Urology; ;3. Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining 272029, China

DOI: https://doi.org/10.16352/j.issn.1001-6325.2024.12.1731
Journal volume & issue: Vol. 44, no. 12
pp. 1731 – 1735

Abstract

Read online

Leukocyte differentiation antigen CD109 (CD109) is a glycosylphosphatidylinositol (GPI)-associated cell surface antigen, belonging to the α-2 macroglobulin/C3, C4 and C5 super family complex, and is a transforming growth factor (TGF)-β/Smads co-receptor. CD109 regulates the occurrence and development of glioma and is closely related to drug resistance and recurrence of glioma. As a cell membrane protein, CD109 can be directly labeled by specific antibodies or enzymes, and may also be recognized by targeted vectors for drug delivery, which is expected to become an effective diagnostic molecular marker and pharmacological therapeutic target.

cd109|glioma|drug resistance|recurrence

Published in Jichu yixue yu linchuang

ISSN: 1001-6325 (Print)
Publisher: Institute of Basic Medical Sciences and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences / Peking Union Medical College.
Country of publisher: China
LCC subjects: Medicine
Website: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/1001-6325/home.shtml

About the journal

Abstract

Keywords